Mercedes Garayoa

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8231572/publications.pdf

Version: 2024-02-01

53 papers	2,577 citations	172207 29 h-index	189595 50 g-index
54 all docs	54 docs citations	54 times ranked	4190 citing authors

#	Article	IF	Citations
1	Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease. Nature Communications, 2021, 12, 421.	5.8	29
2	Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression. Cancers, 2021, 13, 1353.	1.7	22
3	Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma. Cells, 2021, 10, 559.	1.8	2
4	Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression. Cancers, 2021, 13, 2542.	1.7	15
5	Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma. Haematologica, 2020, 105, e116-e120.	1.7	38
6	Filanesib for the treatment of multiple myeloma. Expert Opinion on Investigational Drugs, 2020, 29, 5-14.	1.9	18
7	Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma. Cancers, 2020, 12, 2743.	1.7	9
8	Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: potential antitumour dual agents. MedChemComm, 2019, 10, 1589-1598.	3.5	10
9	Biological Background of Resistance to Current Standards of Care in Multiple Myeloma. Cells, 2019, 8, 1432.	1.8	24
10	Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone. Haematologica, 2017, 102, 168-175.	1.7	9
11	The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma. Haematologica, 2017, 102, 2113-2124.	1.7	19
12	Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair. Journal of Hematology and Oncology, 2017, 10, 127.	6.9	25
13	The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care. Clinical Cancer Research, 2017, 23, 225-238.	3.2	42
14	Effects of IL-8 Up-Regulation on Cell Survival and Osteoclastogenesis in Multiple Myeloma. American Journal of Pathology, 2016, 186, 2171-2182.	1.9	35
15	In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. Leukemia, 2015, 29, 705-714.	3.3	72
16	Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138++ and CD138low Subpopulations in Multiple Myeloma Cell Lines. PLoS ONE, 2014, 9, e92378.	1.1	23
17	Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease. Clinical Cancer Research, 2014, 20, 1542-1554.	3.2	75
18	Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease. Oncotarget, 2014, 5, 8284-8305.	0.8	43

#	Article	IF	Citations
19	Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics. World Journal of Stem Cells, 2014, 6, 322.	1.3	36
20	The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia, 2013, 27, 430-440.	3.3	112
21	RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. Investigational New Drugs, 2013, 31, 200-205.	1.2	11
22	Sphingosineâ€1â€phosphate activates chemokineâ€promoted myeloma cell adhesion and migration involving Î±4Î²1 integrin function. Journal of Pathology, 2013, 229, 36-48.	2.1	30
23	Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood, 2013, 122, 3591-3598.	0.6	131
24	CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. Haematologica, 2012, 97, 1110-1114.	1.7	34
25	Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects. PLoS ONE, 2012, 7, e34914.	1.1	61
26	Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma. Annals of Hematology, 2012, 91, 257-269.	0.8	7
27	Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. Haematologica, 2011, 96, 687-695.	1.7	13
28	In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica, 2010, 95, 794-803.	1.7	144
29	The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair. Leukemia, 2009, 23, 2265-2274.	3.3	58
30	Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia, 2009, 23, 1515-1527.	3.3	122
31	Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood, 2009, 113, 3781-3791.	0.6	78
32	The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. British Journal of Haematology, 2008, 141, 470-482.	1.2	35
33	The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. Haematologica, 2008, 93, 57-66.	1.7	56
34	Aplidin, a Marine Organismâ€“Derived Compound with Potent Antimyeloma Activity In vitro and In vivo. Cancer Research, 2008, 68, 5216-5225.	0.4	98
35	Hypoxia alters the adhesive properties of lymphatic endothelial cells. A transcriptional and functional study. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 880-890.	1.9	49
36	Adrenomedullin Is a Cross-Talk Molecule that Regulates Tumor and Mast Cell Function during Human Carcinogenesis. American Journal of Pathology, 2006, 168, 280-291.	1.9	74

#	Article	IF	Citations
37	Accumulation of hypoxia-inducible factor-1Î± is limited by transcription-dependent depletion. Oncogene, 2005, 24, 4829-4838.	2.6	57
38	Adrenomedullin expression in a rat model of acute lung injury induced by hypoxia and LPS. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2005, 288, L536-L545.	1.3	27
39	Mitogen-Activated Protein Kinase Phosphatase-1 Is Overexpressed in Non-Small Cell Lung Cancer and Is an Independent Predictor of Outcome in Patients. Clinical Cancer Research, 2004, 10, 3639-3649.	3.2	125
40	Expression of Complement Factor H by Lung Cancer Cells. Cancer Research, 2004, 64, 6310-6318.	0.4	108
41	Depressed adrenomedullin in the embryonic transforming growth factor-beta1 null mouse becomes elevated postnatally.. International Journal of Developmental Biology, 2004, 48, 67-70.	0.3	8
42	Androgen-independent expression of adrenomedullin and peptidylglycine Î±-amidating monooxygenase in human prostatic carcinoma. Molecular Carcinogenesis, 2003, 38, 14-24.	1.3	16
43	Leptin Expression in the Rat Ovary Depends on Estrous Cycle. Journal of Histochemistry and Cytochemistry, 2003, 51, 1269-1277.	1.3	43
44	Downregulation of hnRNP A2/B1 Expression in Tumor Cells under Prolonged Hypoxia. American Journal of Respiratory Cell and Molecular Biology, 2003, 28, 80-85.	1.4	23
45	Effects of Acute Hypoxia and Lipopolysaccharide on Nitric Oxide Synthase-2 Expression in Acute Lung Injury. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 287-296.	2.5	40
46	The Effects of Adrenomedullin Overexpression in Breast Tumor Cells. Journal of the National Cancer Institute, 2002, 94, 1226-1237.	3.0	103
47	Adrenomedullin in mammalian embryogenesis. Microscopy Research and Technique, 2002, 57, 40-54.	1.2	25
48	Adrenomedullin functions as an important tumor survival factor in human carcinogenesis. Microscopy Research and Technique, 2002, 57, 110-119.	1.2	46
49	Alternative splicing of the proadrenomedullin gene results in differential expression of gene products. Journal of Molecular Endocrinology, 2001, 27, 31-41.	1.1	39
50	Hypoxia-Inducible Factor-1 (HIF-1) Up-Regulates Adrenomedullin Expression in Human Tumor Cell Lines during Oxygen Deprivation: A Possible Promotion Mechanism of Carcinogenesis. Molecular Endocrinology, 2000, 14, 848-862.	3.7	221
51	The Role of Adrenomedullin as a Growth Regulatory Peptide in the Normal and Malignant Setting. Journal of Animal Science, 1999, 77, 55.	0.2	15
52	Myoendocrine-like Cells in Invertebrates: Occurrence of Noncardiac Striated Secretory-like Myocytes in the Gut of the Ant Formica polyctena. General and Comparative Endocrinology, 1994, 95, 133-142.	0.8	7
53	Malpighian tubules ofFormica polyctena (Hymenoptera): Light and electron microscopic study. Journal of Morphology, 1992, 214, 159-171.	0.6	14